1. Alibhai SMH, Naglie G, Nam R, Trachtenberg J, Krahn MD (2003) Do older men benefit from curative therapy of localized prostate cancer? J Clin Oncol 17:3318–3327
2. Aoki M, Miki K, Kido M, Sasaki H, Nakamura W, Kijima Y, Kobayashi M et al (2014) Analysis of prognostic factors in localized high-risk prostate cancer patients treated with HDR brachytherapy, hypofractionated 3D-CRT and neoadjuvant/adjuvant androgen deprivation therapy (trimodality therapy). J Radiat Res 3:527–532
3. Boehm K, Schiffmann J, Tian Z, Lesmana H, Larcher A, Mandel P, Karakiewicz PI et al (2016) Five-year biochemical recurrence-free and overall survival following high-dose-rate brachytherapy with additional external beam or radical prostatectomy in patients with clinically localized prostate cancer. Urol Oncol 3(119):e11–e18
4. Cancer Research UK (2016) Prostate cancer incidence statistics. Prostate cancer incidence by age.
http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/prostate-cancer/incidence#ref-1
. Accessed 14 June 2018
5. Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies. Development and validation. J Chron Dis 5:373–383